Market News AIOpen the app

The FDA has given the green light for Novo Nordisk's Sogroya® to treat children with Turner Syndrome.

TrialRead the original at prnewswire.com
Good for NVO

Novo Nordisk can now offer Sogroya to children aged 2.5 years and older with Turner syndrome. The trial showed it worked and was safe, though the report gives no sales estimate.

NVO · Novo Nordisk

AI read · Good for NVO

The AI's read

This gives Novo Nordisk another group of children it can treat with Sogroya. The trial showed the treatment worked and was safe for these children. The report gives no sales estimate, so the size of the benefit is unknown.

Get alerts for NVO

Follow Novo Nordisk (NVO) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for NVO
Free on the App Store and Google Play, or on the web.